What Is Pepsinogen From Digestion To Health Biomarker?

Pepsinogen is the inactive precursor of pepsin, the main digestive enzyme in your stomach that breaks down proteins in food. It is produced by cells in the stomach lining and released into the stomach cavity, where stomach acid converts it into active pepsin. Beyond digestion, pepsinogen levels in the blood are used as a clinical biomarker to assess stomach health, particularly for detecting inflammation, atrophy, and assessing the risk of certain gastric conditions.

What Is Pepsinogen and How Does It Work in Digestion?

Pepsinogen is a protein made by chief cells in the gastric glands of the stomach lining. When you eat, these cells release pepsinogen into the stomach. The acidic environment of the stomach, created by hydrochloric acid from parietal cells, triggers a change. The acid clips off a small piece of the pepsinogen molecule, converting it into the active enzyme pepsin.

Pepsin then goes to work breaking down proteins in your food into smaller peptides. This is the first major step in protein digestion. Without this process, your body would struggle to absorb amino acids from dietary protein, which are essential for building and repairing tissues.

Interestingly, pepsinogen is not one single substance. There are two main groups: pepsinogen I (also called pepsinogen A) and pepsinogen II (also called pepsinogen C). They are produced in different parts of the stomach and behave differently in the blood. This distinction matters for medical testing.

Why Is Pepsinogen Used as a Health Biomarker?

Healthy stomach lining produces normal amounts of pepsinogen. When the lining becomes damaged or diseased, those production patterns change. This is why doctors and researchers measure pepsinogen levels in the blood as a window into what is happening inside the stomach without needing an endoscopy.

The key insight is that pepsinogen I is produced in the upper part of the stomach, the fundus and body. Pepsinogen II is produced throughout the entire stomach. When the stomach lining atrophies, or thins out, the cells that make pepsinogen I are lost first. This causes a drop in pepsinogen I levels while pepsinogen II levels stay relatively stable.

This is why the ratio of pepsinogen I to pepsinogen II is so useful. A low ratio, combined with low absolute pepsinogen I levels, strongly suggests atrophy of the stomach lining. This condition is a known precursor to more serious gastric issues, including stomach cancer.

What Can Pepsinogen Levels Tell Your Doctor?

Blood tests for pepsinogen are most commonly used to evaluate the health of the stomach mucosa, the inner lining. The main clinical applications include screening for chronic atrophic gastritis and assessing the risk of gastric cancer.

Chronic atrophic gastritis is a condition where the stomach lining becomes chronically inflamed and gradually thins. It is often caused by long-term infection with Helicobacter pylori, a common bacterium, or by an autoimmune reaction. Many people with this condition have no symptoms initially, which is why a blood test can be valuable.

Research has shown that low pepsinogen I levels and a low pepsinogen I/II ratio correlate with the presence of gastric atrophy. In countries with high rates of stomach cancer, such as Japan, pepsinogen testing is part of national screening programs. The test helps identify people who need a follow-up endoscopy for a definitive diagnosis.

It is important to understand what the test does not do. A pepsinogen blood test is a screening tool, not a diagnostic test. It flags risk. It cannot confirm the presence of cancer or definitively diagnose any condition. An abnormal result means you should discuss further evaluation with your doctor.

How Is the Pepsinogen Test Performed and Interpreted?

The test is a simple blood draw. No special preparation is required, though your doctor may advise fasting if other tests are being done at the same time. The blood sample is sent to a laboratory where levels of pepsinogen I and pepsinogen II are measured, and the ratio is calculated.

Interpreting the results requires clinical judgment. Different laboratories may use slightly different reference ranges. Generally, a pepsinogen I level below a certain threshold and a pepsinogen I/II ratio below a certain value are considered suspicious for gastric atrophy.

Your doctor will interpret the results in the context of your age, symptoms, family history, and other risk factors. An abnormal result does not mean you have cancer. It means your stomach lining may be damaged and deserves a closer look, usually with an upper endoscopy.

What Are the Limitations of Pepsinogen Testing?

Pepsinogen testing is a valuable tool, but it has limitations. The test is most accurate for detecting atrophy in the body of the stomach. Atrophy that is limited to the lower part of the stomach, the antrum, may not produce the same pattern of pepsinogen changes. This can lead to false negatives.

Some medications can affect pepsinogen levels. Proton pump inhibitors, commonly used for acid reflux, can raise pepsinogen levels. This can potentially mask atrophy and create false reassurance. If you take these medications, your doctor may ask you to pause them before testing, though you should never stop a prescribed medication without medical guidance.

There is also the question of what to do with borderline results. A mildly low ratio may not be clinically significant in a young person with no symptoms. In an older person with other risk factors, the same result may warrant further investigation. Test results are never interpreted in isolation.

How Does Pepsinogen Compare to Other Stomach Health Tests?

Pepsinogen testing is one option among several for evaluating stomach health. The most direct method is endoscopy with biopsy, where a thin tube with a camera is inserted through the mouth into the stomach, and small tissue samples are taken. This is the gold standard for diagnosing gastric atrophy and other mucosal conditions.

Blood tests for Helicobacter pylori antibodies can indicate past or present infection. Stool antigen tests and urea breath tests can detect active infection. Since H. pylori is a major cause of gastric atrophy, these tests are often used alongside pepsinogen testing.

Another blood biomarker, gastrin-17, reflects the function of the lower part of the stomach. Some panels combine pepsinogen I, pepsinogen II, gastrin-17, and H. pylori antibodies to create a more complete picture of stomach health. This combined approach is sometimes called the “serological gastric biopsy” because it provides functional information without invasive procedures.

Who Should Consider Pepsinogen Testing?

There is no universal consensus on who should be screened with pepsinogen testing. In countries with high gastric cancer rates, screening programs include it. In the United States, where gastric cancer is less common, testing is typically reserved for people with specific risk factors.

Those risk factors include a family history of gastric cancer, previous H. pylori infection, long-term gastritis, pernicious anemia, or being over a certain age with new digestive symptoms. People who have had partial gastrectomy surgery may also be monitored with pepsinogen testing.

If you are concerned about your stomach health, talk to your doctor. They can assess your individual risk and determine whether pepsinogen testing is appropriate for you. Do not request the test without understanding what the results would mean for your care. A screening test is only useful if you are prepared to act on the results.

What Do Research and Guidelines Say About Pepsinogen?

Extensive research supports the link between low pepsinogen levels and gastric atrophy. Studies have consistently shown that the pepsinogen I/II ratio is a reliable indicator of mucosal health. This evidence base is strongest in Asian populations, where large-scale screening programs have been implemented.

Clinical guidelines from major gastroenterology organizations acknowledge the utility of pepsinogen testing in specific contexts. However, recommendations vary by region and by individual patient factors. The evidence is solid for using pepsinogen as a risk stratification tool, but it is not a replacement for endoscopy when cancer is suspected.

Some research has explored whether pepsinogen testing can reduce the number of unnecessary endoscopies. By identifying low-risk individuals, the test could help allocate invasive procedures to those who need them most. This is an area of active investigation, and results are promising but not definitive.